Overview

XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
0
Participant gender:
All
Summary
This multicenter observational study will evaluate the efficacy and safety of Xeloda (capecitabine) in combination with docetaxel in first-line therapy in participants with HER2-negative metastatic breast cancer. Participants will be followed for approximately 6 months of treatment.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Capecitabine
Docetaxel
Criteria
Inclusion Criteria:

- Adult participants, >/= 18 years of age

- HER2-negative metastatic breast cancer

- Participants initiated on first-line therapy with Xeloda and docetaxel in accordance
with the Summary of Product Characteristics; participants who started treatment with
Xeloda and docetaxel no more than 3 months before enrollment in this study are also
eligible

Exclusion Criteria:

- Contraindications to Xeloda treatment according to the Summary of Product
Characteristics